Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Biogen (BIIB) was downgraded to hold by Jefferies over an anticipated royalty cut for Ocrevus, lackluster pipeline, and expected modest sales of Leqembi. Read more here.

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...

Recently, Eisai and Biogen announced the approval of LEQEMBI in Mexico for early Alzheimer's treatment, following successful Phase 3 trials. This approval, along with ongoing reviews in 16 other ...

Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...

The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the ...

BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of ...